Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer - Abstract

PURPOSE: To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer.

MATERIALS AND METHODS: This clinical trial was performed on 16 patients with hormone-resistant prostate cancer.

RESULTS: Mean age of the participants was 72.7 ± 5.39 years (range, 65 to 85 years). In 94% of patients who received the drug combination, prostate-specific antigen level decreased more than 50%. The mean time to progression was 15 months and mean survival time was 23 months. This combination therapy had some adverse events.

CONCLUSION: Addition of anti-angiogenic agents, such as thalidomide, can improve therapeutic outcome in this group of patients.

Written by:
Rezvani H, Haghighi S, Ghadyani M, Attarian H.   Are you the author?
Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Reference: Urol J. 2012 Fall;9(4):673-7.


PubMed Abstract
PMID: 23235972